S

Summit Therapeutics

D
SMMT
USD
-1.4
(-5.705%)
Pre Open
1,320.00
Volume
-0.19794
EPS
-
Div Yield
-211.363630
P/E
17,005,358,510.66
Market Cap
Today
-5.7050%
1 Week
-15.671%
1 Month
89.052%
6 Months
538.345%
12 Months
1,124.339%
Year To Date
784.895%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SGMO
0.0617
(7.3584%)
USD
B
BGNE
1.56
(0.791%)
USD
C
CERS
0.03
(1.676%)
USD
A
AVXL
0.255
(4.6279%)
USD
O
ONTX
(%)
USD
V
VYGR
0.07
(1.1236%)
USD
A
ADVM
0.5
(7.1633%)
USD
I
IMGN
(%)
USD
T
TXG
1.41
(6.3888%)
USD

Title:
Summit Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Do you need help or have a question?
Contact Us